Medicenna Therapeutics Corp
TSX:MDNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hebei Sailhero Environmental Protection High-tech Co Ltd
SZSE:300137
|
CN |
Medicenna Therapeutics Corp
Non-Reccuring Items
Medicenna Therapeutics Corp
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medicenna Therapeutics Corp
TSX:MDNA
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Non-Reccuring Items
-$1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Non-Reccuring Items
-CA$1.6m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Non-Reccuring Items
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Medicenna Therapeutics Corp
Glance View
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The company went IPO on 2015-07-13. The firm is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The firm has not earned any revenues from its products.
